Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 1/2 1

Status

Terminated 1Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Dermatologic 23Genitourinary 5Thoracic 4Gastrointestinal 3Head & Neck 2Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 244Lung Neoplasms 77Melanoma 57Carcinoma, Renal Cell 44Small Cell Lung Carcinoma 33Colorectal Neoplasms 28Squamous Cell Carcinoma of Head and Neck 24Carcinoma, Transitional Cell 24Neoplasms 23Triple Negative Breast Neoplasms 22Neoplasm Metastasis 21Carcinoma, Hepatocellular 19Ovarian Neoplasms 17Mesothelioma 17Pancreatic Neoplasms 15Mesothelioma, Malignant 15Stomach Neoplasms 13Breast Neoplasms 13Uterine Cervical Neoplasms 12Urinary Bladder Neoplasms 10Head and Neck Neoplasms 10Carcinoma, Merkel Cell 10Kidney Neoplasms 9Adenocarcinoma of Lung 8Esophageal Neoplasms 7Endometrial Neoplasms 7Lymphoma 6Carcinoma, Squamous Cell 6Brain Neoplasms 6Prostatic Neoplasms 5

Interventions

pembrolizumab 4Nivolumab 4Ipilimumab 2Interleukin-2 2Drug Therapy 2Biopsy 2poly ICLC 1pertuzumab 1osimertinib 1montanide ISA 51 1liposomal doxorubicin 1cobimetinib 1cemiplimab 1cc-486 1brodalumab 1atezolizumab 1Trastuzumab 1Tissue Banks 1Standard of Care 1Specimen Handling 1Radiotherapy, Image-Guided 1Radiotherapy 1Quality of Life 1Psychiatric Rehabilitation 1Poly I-C 1Patient Reported Outcome Measures 1Paclitaxel 1Oxaliplatin 1Observation 1Molecular Diagnostic Techniques 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Skin Neoplasms × Nivolumab × Thoracic × Clear all
NCT06362369 2026-04-13

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

7 Hills Pharma, LLC

Phase 1/2 Recruiting
126 enrolled
DermatologicGastrointestinalGenitourinaryOther solid neoplasmThoracic

Turcot syndrome, Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Kidney Neoplasms, Liver Neoplasms, Melanoma, Neoplasm Metastasis, Skin Neoplasms, Colorectal Neoplasms

NCT05704985 2025-05-29

Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors

DEKA Biosciences

Phase 1 Active not recruiting
39 enrolled
DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Kidney Neoplasms, Neoplasms, Pancreatic Neoplasms, Skin Neoplasms, Colorectal Neoplasms

NCT04311710 2023-02-24

CheckMate 76U

Bristol-Myers Squibb

Phase 1 Terminated
21 enrolled
DermatologicGastrointestinalGenitourinaryThoracic

Urinary Bladder Neoplasms, Kidney Neoplasms, Liver Neoplasms, Lung Neoplasms, Neoplasms, Skin Neoplasms

NCT02897765 2021-02-25

A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer

BioNTech SE

Phase 1 Completed
34 enrolled
DermatologicGenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡